• +1-646-491-9876
    • +91-20-67278686

    Search

    Malignant Mesothelioma - Pipeline Review, H1 2017

    Malignant Mesothelioma - Pipeline Review, H1 2017

    • Report Code ID: RW0001709462
    • Category Pharmaceuticals
    • No. of Pages 511
    • Publication Month Mar-17
    • Publisher Name Global Markets Direct
    Malignant Mesothelioma - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Malignant Mesothelioma - Pipeline Review, H1 2017, provides an overview of the Malignant Mesothelioma (Oncology) pipeline landscape.

    Malignant pleural mesothelioma is a rare cancer often diagnosed in people who have been exposed to high levels of asbestos. The malignancy affects the pleura, a thin membrane of lubricating cells that lines the lungs and chest wall. Peritoneal mesothelioma originates in the abdomen and as a result, symptoms often include abdominal pain, weight loss, nausea, and vomiting. Other symptoms include anemia, bowel obstructions, chest pain and hemoptysis.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Malignant Mesothelioma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Malignant Mesothelioma (Oncology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Malignant Mesothelioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Malignant Mesothelioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 5, 30, 27, 14 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 3, 7 and 6 molecules, respectively.

    Malignant Mesothelioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Malignant Mesothelioma (Oncology) .
    - The pipeline guide reviews pipeline therapeutics for Malignant Mesothelioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Malignant Mesothelioma (Oncology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Malignant Mesothelioma (Oncology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Malignant Mesothelioma (Oncology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Malignant Mesothelioma (Oncology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Malignant Mesothelioma (Oncology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    List of Tables 7
    List of Figures 8
    Introduction 10
    Publisher Report Coverage 10
    Malignant Mesothelioma - Overview 11
    Malignant Mesothelioma - Therapeutics Development 12
    Pipeline Overview 12
    Pipeline by Companies 13
    Pipeline by Universities/Institutes 18
    Products under Development by Companies 19
    Products under Development by Universities/Institutes 24
    Malignant Mesothelioma - Therapeutics Assessment 25
    Assessment by Target 25
    Assessment by Mechanism of Action 30
    Assessment by Route of Administration 35
    Assessment by Molecule Type 37
    Malignant Mesothelioma - Companies Involved in Therapeutics Development 39
    Aduro BioTech Inc 39
    Advantagene Inc 39
    Amphera BV 40
    AnGes MG Inc 40
    arGEN-X BV 41
    ArQule Inc 41
    AVEO Pharmaceuticals Inc 42
    Bayer AG 42
    Biogen Inc 43
    Bionomics Ltd 43
    Biotecnol Ltd 44
    Boehringer Ingelheim GmbH 44
    Boston Biomedical Inc 45
    Bristol-Myers Squibb Company 45
    Calithera Biosciences Inc 46
    CanBas Co Ltd 46
    CBT Pharmaceuticals Inc 47
    Concordia International Corp 47
    Eagle Pharmaceuticals Inc 48
    Eisai Co Ltd 48
    Eli Lilly and Company 49
    EnGeneIC Ltd 49
    EpiZyme Inc 50
    F. Hoffmann-La Roche Ltd 50
    Five Prime Therapeutics Inc 51
    Genelux Corp 51
    GlaxoSmithKline Plc 52
    Horizon Pharma Plc 52
    Inventiva 53
    Juno Therapeutics Inc 53
    Karyopharm Therapeutics Inc 54
    MacroGenics Inc 54
    MedImmune LLC 55
    Merck & Co Inc 55
    Merck KGaA 56
    Millennium Pharmaceuticals Inc 56
    MolMed SpA 57
    Morphotek Inc 57
    Novartis AG 58
    Ono Pharmaceutical Co Ltd 59
    OSE Immunotherapeutics 59
    Oxford BioMedica Plc 60
    Pharma Mar SA 60
    Philogen SpA 61
    Polaris Pharmaceuticals Inc 61
    Progenra Inc 62
    Seattle Genetics Inc 62
    Sellas Inc 63
    Targovax ASA 63
    TRACON Pharmaceuticals Inc 64
    TREAT U SA 64
    UbiVac LLC 65
    VasGene Therapeutics Inc 65
    Verastem Inc 66
    Virttu Biologics Ltd 66
    Vyriad Inc 67
    Y's Therapeutics Co Ltd 67
    Malignant Mesothelioma - Drug Profiles 68
    (epirubicin + staurosporine) - Drug Profile 68
    alisertib - Drug Profile 69
    amatuximab - Drug Profile 75
    anetumab ravtansine - Drug Profile 78
    ARGX-110 - Drug Profile 81
    atezolizumab - Drug Profile 86
    AV-203 - Drug Profile 103
    avelumab - Drug Profile 106
    bevacizumab - Drug Profile 115
    BG-00001 - Drug Profile 127
    birabresib - Drug Profile 128
    BMS-986148 - Drug Profile 131
    BNC-105 - Drug Profile 132
    brentuximab vedotin - Drug Profile 138
    CB-839 - Drug Profile 165
    CBP-501 - Drug Profile 174
    CBT-501 - Drug Profile 177
    Cellular Immunotherapy for Oncology - Drug Profile 178
    Cellular Immunotherapy to Target Mesothelin for Malignant Pleural Mesothelioma and Advanced Leukemia - Drug Profile 179
    Cellular Immunotherapy to Target Mesothelin for Oncology - Drug Profile 180
    Cellular Immunotherapy to Target WT1 for Oncology - Drug Profile 181
    cisplatin - Drug Profile 182
    CRS-207 - Drug Profile 183
    CSG-MESO - Drug Profile 190
    defactinib hydrochloride - Drug Profile 191
    DFP-10825 - Drug Profile 199
    doxorubicin hydrochloride - Drug Profile 200
    DPV-001 - Drug Profile 201
    durvalumab - Drug Profile 203
    durvalumab + tremelimumab - Drug Profile 217
    E-7449 - Drug Profile 223
    emactuzumab - Drug Profile 224
    enoblituzumab - Drug Profile 225
    ESK-1 - Drug Profile 228
    FL-118 - Drug Profile 229
    FP-1039 - Drug Profile 232
    galinpepimut-S - Drug Profile 236
    ganetespib - Drug Profile 240
    GEN-0101 - Drug Profile 254
    Gene Therapy for Glioblastoma and Mesothelioma - Drug Profile 256
    Gene Therapy for Malignant Pleural Effusion and Solid Tumors - Drug Profile 257
    Gene Therapy to Activate NK4 for Malignant Pleural Mesothelioma - Drug Profile 258
    GLONC-1 - Drug Profile 259
    GSK-2256098 - Drug Profile 263
    GSK-3359609 - Drug Profile 265
    HSV-1716 - Drug Profile 266
    HXR-9 - Drug Profile 270
    iCasp9M28z - Drug Profile 271
    interferon gamma-1b - Drug Profile 272
    ipilimumab + nivolumab - Drug Profile 277
    JTCR-016 - Drug Profile 281
    KPT-251 - Drug Profile 283
    KPT-276 - Drug Profile 284
    LEU-001 - Drug Profile 285
    lurbinectedin - Drug Profile 286
    LY-3023414 - Drug Profile 294
    MesoCancerVac - Drug Profile 296
    MesoCART - Drug Profile 297
    MGD-009 - Drug Profile 298
    Monoclonal Antibody Conjugate to Target Mesothelin for Malignant Mesothelioma - Drug Profile 300
    Monoclonal Antibody Conjugate to Target Mesothelin for Oncology - Drug Profile 301
    MTG-201 - Drug Profile 303
    MTG-202 - Drug Profile 305
    napabucasin - Drug Profile 306
    NGR-hTNF - Drug Profile 314
    nintedanib - Drug Profile 320
    nivolumab - Drug Profile 331
    Oncolytic Virus for Malignant Pleural Mesothelioma - Drug Profile 372
    Oncolytic Virus to Target CD46 and SLC5A5 for Malignant Pleural Mesothelioma - Drug Profile 373
    ONCOS-102 - Drug Profile 374
    OSE-2101 - Drug Profile 377
    Oshadi D + Oshadi R - Drug Profile 380
    OXB-301 - Drug Profile 381
    P-0005091 - Drug Profile 385
    pegargiminase - Drug Profile 386
    pembrolizumab - Drug Profile 395
    pemetrexed disodium - Drug Profile 443
    porfimer sodium - Drug Profile 444
    rAd-IFN - Drug Profile 446
    RG-7787 - Drug Profile 449
    S-588210 - Drug Profile 451
    Small Molecule for Malignant Mesothelioma and Asbestosis - Drug Profile 452
    Small Molecule for Oncology - Drug Profile 453
    Stem Cell Therapy to Target TRAIL Receptor for Malignant Pleural Mesothelioma and Metastatic Lung Cancer - Drug Profile 454
    TargomiRs - Drug Profile 455
    tazemetostat - Drug Profile 457
    TB-535 - Drug Profile 466
    Teleukin - Drug Profile 467
    tivantinib - Drug Profile 469
    trabectedin - Drug Profile 475
    TRC-102 - Drug Profile 482
    Vaccine to target Mesothelin for Mesothelioma and Ovarian Cancer - Drug Profile 484
    Vaccine to Target WT1 for Oncology - Drug Profile 485
    Vas-01 - Drug Profile 486
    YS-110 - Drug Profile 488
    Malignant Mesothelioma - Dormant Projects 490
    Malignant Mesothelioma - Discontinued Products 492
    Malignant Mesothelioma - Product Development Milestones 493
    Featured News & Press Releases 493
    Appendix 504
    Methodology 504
    Coverage 504
    Secondary Research 504
    Primary Research 504
    Expert Panel Validation 504
    Contact Us 504
    Disclaimer 505

    List of Tables

    Number of Products under Development for Malignant Mesothelioma, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..4) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..2) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..3) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3) , H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Malignant Mesothelioma - Pipeline by Aduro BioTech Inc, H1 2017
    Malignant Mesothelioma - Pipeline by Advantagene Inc, H1 2017
    Malignant Mesothelioma - Pipeline by Amphera BV, H1 2017
    Malignant Mesothelioma - Pipeline by AnGes MG Inc, H1 2017
    Malignant Mesothelioma - Pipeline by arGEN-X BV, H1 2017
    Malignant Mesothelioma - Pipeline by ArQule Inc, H1 2017
    Malignant Mesothelioma - Pipeline by AVEO Pharmaceuticals Inc, H1 2017
    Malignant Mesothelioma - Pipeline by Bayer AG, H1 2017
    Malignant Mesothelioma - Pipeline by Biogen Inc, H1 2017
    Malignant Mesothelioma - Pipeline by Bionomics Ltd, H1 2017
    Malignant Mesothelioma - Pipeline by Biotecnol Ltd, H1 2017
    Malignant Mesothelioma - Pipeline by Boehringer Ingelheim GmbH, H1 2017
    Malignant Mesothelioma - Pipeline by Boston Biomedical Inc, H1 2017
    Malignant Mesothelioma - Pipeline by Bristol-Myers Squibb Company, H1 2017
    Malignant Mesothelioma - Pipeline by Calithera Biosciences Inc, H1 2017
    Malignant Mesothelioma - Pipeline by CanBas Co Ltd, H1 2017
    Malignant Mesothelioma - Pipeline by CBT Pharmaceuticals Inc, H1 2017
    Malignant Mesothelioma - Pipeline by Concordia International Corp, H1 2017
    Malignant Mesothelioma - Pipeline by Eagle Pharmaceuticals Inc, H1 2017
    Malignant Mesothelioma - Pipeline by Eisai Co Ltd, H1 2017
    Malignant Mesothelioma - Pipeline by Eli Lilly and Company, H1 2017
    Malignant Mesothelioma - Pipeline by EnGeneIC Ltd, H1 2017
    Malignant Mesothelioma - Pipeline by EpiZyme Inc, H1 2017
    Malignant Mesothelioma - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
    Malignant Mesothelioma - Pipeline by Five Prime Therapeutics Inc, H1 2017
    Malignant Mesothelioma - Pipeline by Genelux Corp, H1 2017
    Malignant Mesothelioma - Pipeline by GlaxoSmithKline Plc, H1 2017
    Malignant Mesothelioma - Pipeline by Horizon Pharma Plc, H1 2017
    Malignant Mesothelioma - Pipeline by Inventiva, H1 2017
    Malignant Mesothelioma - Pipeline by Juno Therapeutics Inc, H1 2017
    Malignant Mesothelioma - Pipeline by Karyopharm Therapeutics Inc, H1 2017
    Malignant Mesothelioma - Pipeline by MacroGenics Inc, H1 2017
    Malignant Mesothelioma - Pipeline by MedImmune LLC, H1 2017
    Malignant Mesothelioma - Pipeline by Merck & Co Inc, H1 2017
    Malignant Mesothelioma - Pipeline by Merck KGaA, H1 2017
    Malignant Mesothelioma - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
    Malignant Mesothelioma - Pipeline by MolMed SpA, H1 2017
    Malignant Mesothelioma - Pipeline by Morphotek Inc, H1 2017
    Malignant Mesothelioma - Pipeline by Novartis AG, H1 2017
    Malignant Mesothelioma - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
    Malignant Mesothelioma - Pipeline by OSE Immunotherapeutics, H1 2017
    Malignant Mesothelioma - Pipeline by Oxford BioMedica Plc, H1 2017
    Malignant Mesothelioma - Pipeline by Pharma Mar SA, H1 2017
    Malignant Mesothelioma - Pipeline by Philogen SpA, H1 2017
    Malignant Mesothelioma - Pipeline by Polaris Pharmaceuticals Inc, H1 2017
    Malignant Mesothelioma - Pipeline by Progenra Inc, H1 2017
    Malignant Mesothelioma - Pipeline by Seattle Genetics Inc, H1 2017
    Malignant Mesothelioma - Pipeline by Sellas Inc, H1 2017
    Malignant Mesothelioma - Pipeline by Targovax ASA, H1 2017
    Malignant Mesothelioma - Pipeline by TRACON Pharmaceuticals Inc, H1 2017
    Malignant Mesothelioma - Pipeline by TREAT U SA, H1 2017
    Malignant Mesothelioma - Pipeline by UbiVac LLC, H1 2017
    Malignant Mesothelioma - Pipeline by VasGene Therapeutics Inc, H1 2017
    Malignant Mesothelioma - Pipeline by Verastem Inc, H1 2017
    Malignant Mesothelioma - Pipeline by Virttu Biologics Ltd, H1 2017
    Malignant Mesothelioma - Pipeline by Vyriad Inc, H1 2017
    Malignant Mesothelioma - Pipeline by Y's Therapeutics Co Ltd, H1 2017
    Malignant Mesothelioma - Dormant Projects, H1 2017
    Malignant Mesothelioma - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Malignant Mesothelioma - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Malignant Mesothelioma, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Top 10 Routes of Administration, H1 2017
    Number of Products by Stage and Top 10 Routes of Administration, H1 2017
    Number of Products by Top 10 Molecule Types, H1 2017
    Number of Products by Stage and Top 10 Molecule Types, H1 2017
    Aduro BioTech Inc
    Advantagene Inc
    Amphera BV
    AnGes MG Inc
    arGEN-X BV
    ArQule Inc
    AVEO Pharmaceuticals Inc
    Bayer AG
    Biogen Inc
    Bionomics Ltd
    Biotecnol Ltd
    Boehringer Ingelheim GmbH
    Boston Biomedical Inc
    Bristol-Myers Squibb Company
    Calithera Biosciences Inc
    CanBas Co Ltd
    CBT Pharmaceuticals Inc
    Concordia International Corp
    Eagle Pharmaceuticals Inc
    Eisai Co Ltd
    Eli Lilly and Company
    EnGeneIC Ltd
    EpiZyme Inc
    F. Hoffmann-La Roche Ltd
    Five Prime Therapeutics Inc
    Genelux Corp
    GlaxoSmithKline Plc
    Horizon Pharma Plc
    Inventiva
    Juno Therapeutics Inc
    Karyopharm Therapeutics Inc
    MacroGenics Inc
    MedImmune LLC
    Merck & Co Inc
    Merck KGaA
    Millennium Pharmaceuticals Inc
    MolMed SpA
    Morphotek Inc
    Novartis AG
    Ono Pharmaceutical Co Ltd
    OSE Immunotherapeutics
    Oxford BioMedica Plc
    Pharma Mar SA
    Philogen SpA
    Polaris Pharmaceuticals Inc
    Progenra Inc
    Seattle Genetics Inc
    Sellas Inc
    Targovax ASA
    TRACON Pharmaceuticals Inc
    TREAT U SA
    UbiVac LLC
    VasGene Therapeutics Inc
    Verastem Inc
    Virttu Biologics Ltd
    Vyriad Inc
    Y's Therapeutics Co Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//malignant-mesothelioma-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//malignant-mesothelioma-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//malignant-mesothelioma-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments